Alembic Pharmaceuticals Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹741.55
- Today's High:
- ₹799.95
- Open Price:
- ₹765.8
- 52W Low:
- ₹458.2376
- 52W High:
- ₹797.95
- Prev. Close:
- ₹764.8
- Volume:
- 411471
Company Statistics
- Market Cap.:
- ₹152.37 billion
- Book Value:
- 222.344
- Revenue TTM:
- ₹58.77 billion
- Operating Margin TTM:
- 10.6%
- Gross Profit TTM:
- ₹39.44 billion
- Profit Margin:
- 8.99%
- Return on Assets TTM:
- 4.11%
- Return on Equity TTM:
- 7.12%
Company Profile
Alembic Pharmaceuticals Limited had its IPO on under the ticker symbol APLLTD.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Alembic Pharmaceuticals Limited has a staff strength of 14,593 employees.
Stock update
Shares of Alembic Pharmaceuticals Limited opened at ₹765.8 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹741.55 - ₹799.95, and closed at ₹751.05.
This is a -1.8% slip from the previous day's closing price.
A total volume of 411,471 shares were traded at the close of the day’s session.
In the last one week, shares of Alembic Pharmaceuticals Limited have slipped by -2.48%.
Alembic Pharmaceuticals Limited's Key Ratios
Alembic Pharmaceuticals Limited has a market cap of ₹152.37 billion, indicating a price to book ratio of 2.1853 and a price to sales ratio of 2.0915.
In the last 12-months Alembic Pharmaceuticals Limited’s revenue was ₹58.77 billion with a gross profit of ₹39.44 billion and an EBITDA of ₹8.78 billion. The EBITDA ratio measures Alembic Pharmaceuticals Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Alembic Pharmaceuticals Limited’s operating margin was 10.6% while its return on assets stood at 4.11% with a return of equity of 7.12%.
In Q2, Alembic Pharmaceuticals Limited’s quarterly earnings growth was a positive 1327.4% while revenue growth was a positive 17.7%.
Alembic Pharmaceuticals Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 28.7946
- PEG
Its diluted EPS in the last 12-months stands at ₹26.92 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alembic Pharmaceuticals Limited’s profitability.
Alembic Pharmaceuticals Limited stock is trading at a EV to sales ratio of 2.2344 and a EV to EBITDA ratio of 17.6806. Its price to sales ratio in the trailing 12-months stood at 2.0915.
Alembic Pharmaceuticals Limited stock pays annual dividends of ₹8 per share, indicating a yield of 1.04% and a payout ratio of 29.75%.
Balance sheet and cash flow metrics
- Total Assets
- ₹61.83 billion
- Total Liabilities
- ₹16.37 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 29.75%
Alembic Pharmaceuticals Limited ended 2024 with ₹61.83 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹61.83 billion while shareholder equity stood at ₹43.70 billion.
Alembic Pharmaceuticals Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹16.37 billion in other current liabilities, 393100000.00 in common stock, ₹43.31 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹754.80 million and cash and short-term investments were ₹853.30 million. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.
Alembic Pharmaceuticals Limited’s total current assets stands at ₹29.10 billion while long-term investments were ₹0 and short-term investments were ₹98.50 million. Its net receivables were ₹10.46 billion compared to accounts payable of ₹6.80 billion and inventory worth ₹14.75 billion.
In 2024, Alembic Pharmaceuticals Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Alembic Pharmaceuticals Limited paid ₹0.30 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹751.05
- 52-Week High
- ₹797.95
- 52-Week Low
- ₹458.2376
- Analyst Target Price
- ₹
Alembic Pharmaceuticals Limited stock is currently trading at ₹751.05 per share. It touched a 52-week high of ₹797.95 and a 52-week low of ₹797.95. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹733.69 and 200-day moving average was ₹593.44 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 7068% of the company’s stock are held by insiders while 1345% are held by institutions.
Frequently Asked Questions About Alembic Pharmaceuticals Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.